Research
Hormonal
The relationship among cardiovascular disease, chronic kidney disease, and metabolic diseases is recognized as 'cardiovascular-kidney-metabolic (CKM) syndrome'.
Clinicians should consider the interconnectedness of these diseases in treatment.
StrongSupportsmedium confidence
The relationship among cardiovascular disease, chronic kidney disease, and metabolic diseases, including obesity and diabetes, has now been recognized as 'cardiovascular-kidney-metabolic (CKM) syndrome'.
Why this rating
The claim is based on a comprehensive understanding of the relationship among diseases.
Source
The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome
Sonal Kumar et al. · JACC Advances · 2026
DOI 10.1016/j.jacadv.2025.102465
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →